Your browser doesn't support javascript.
loading
Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK.
McCarthy, Grant; Fenu, Elisabetta; Bennett, Natalie; Almond, Chrissy.
Affiliation
  • McCarthy G; BresMed Health Solutions Ltd, Sheffield, UK.
  • Fenu E; BresMed Health Solutions Ltd, Sheffield, UK.
  • Bennett N; Novartis Pharmaceuticals UK Limited, Camberley, Surrey, UK. natalie.bennett@novartis.com.
  • Almond C; BresMed Health Solutions Ltd, Sheffield, UK.
Adv Ther ; 36(3): 632-644, 2019 03.
Article in En | MEDLINE | ID: mdl-30726549
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Visual Acuity / Choroidal Neovascularization / Angiogenesis Inhibitors / Ranibizumab Type of study: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: Europa Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2019 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Visual Acuity / Choroidal Neovascularization / Angiogenesis Inhibitors / Ranibizumab Type of study: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: Europa Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2019 Document type: Article Affiliation country: Country of publication: